Mizuho raised the firm’s price target on Harmony Biosciences to $42 from $33 and keeps a Buy rating on the shares. Ahead of Q4 earnings, the firm updated models and revised 12-month price targets in the biotechnology space.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HRMY: